BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 14616999)

  • 1. Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia.
    Tiesmeier J; Czwalinna A; Müller-Tidow C; Krauter J; Serve H; Heil G; Ganser A; Verbeek W
    Br J Haematol; 2003 Nov; 123(3):413-9. PubMed ID: 14616999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML.
    Kaeferstein A; Krug U; Tiesmeier J; Aivado M; Faulhaber M; Stadler M; Krauter J; Germing U; Hofmann WK; Koeffler HP; Ganser A; Verbeek W
    Leukemia; 2003 Feb; 17(2):343-9. PubMed ID: 12592334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias.
    Gombart AF; Hofmann WK; Kawano S; Takeuchi S; Krug U; Kwok SH; Larsen RJ; Asou H; Miller CW; Hoelzer D; Koeffler HP
    Blood; 2002 Feb; 99(4):1332-40. PubMed ID: 11830484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models.
    Kato N; Kitaura J; Doki N; Komeno Y; Watanabe-Okochi N; Togami K; Nakahara F; Oki T; Enomoto Y; Fukuchi Y; Nakajima H; Harada Y; Harada H; Kitamura T
    Blood; 2011 Jan; 117(1):221-33. PubMed ID: 20884804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.
    Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; Meijer J; van Oosterhoud S; van Putten WL; Valk PJ; Berna Beverloo H; Tenen DG; Löwenberg B; Delwel R
    Hematol J; 2003; 4(1):31-40. PubMed ID: 12692518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.
    Lin LI; Chen CY; Lin DT; Tsay W; Tang JL; Yeh YC; Shen HL; Su FH; Yao M; Huang SY; Tien HF
    Clin Cancer Res; 2005 Feb; 11(4):1372-9. PubMed ID: 15746035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C/EBPα-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia.
    Hughes JM; Legnini I; Salvatori B; Masciarelli S; Marchioni M; Fazi F; Morlando M; Bozzoni I; Fatica A
    Oncotarget; 2015 Jul; 6(21):18534-44. PubMed ID: 26053097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene.
    Asou H; Gombart AF; Takeuchi S; Tanaka H; Tanioka M; Matsui H; Kimura A; Inaba T; Koeffler HP
    Genes Chromosomes Cancer; 2003 Feb; 36(2):167-74. PubMed ID: 12508245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A family harboring a germ-line N-terminal C/EBPalpha mutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPalpha mutation.
    Nanri T; Uike N; Kawakita T; Iwanaga E; Mitsuya H; Asou N
    Genes Chromosomes Cancer; 2010 Mar; 49(3):237-41. PubMed ID: 19953636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AML patients with CEBPalpha mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples.
    Shih LY; Liang DC; Huang CF; Wu JH; Lin TL; Wang PN; Dunn P; Kuo MC; Tang TC
    Leukemia; 2006 Apr; 20(4):604-9. PubMed ID: 16453003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A C-terminal mutant of CCAAT-enhancer-binding protein α (C/EBPα-Cm) downregulates Csf1r, a potent accelerator in the progression of acute myeloid leukemia with C/EBPα-Cm.
    Togami K; Kitaura J; Uchida T; Inoue D; Nishimura K; Kawabata KC; Nagase R; Horikawa S; Izawa K; Fukuyama T; Nakahara F; Oki T; Harada Y; Harada H; Aburatani H; Kitamura T
    Exp Hematol; 2015 Apr; 43(4):300-8.e1. PubMed ID: 25534203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50.
    Paz-Priel I; Cai DH; Wang D; Kowalski J; Blackford A; Liu H; Heckman CA; Gombart AF; Koeffler HP; Boxer LM; Friedman AD
    Mol Cancer Res; 2005 Oct; 3(10):585-96. PubMed ID: 16254192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of CCAAT/enhancer binding protein alpha gene mutations in acute myeloid leukemia].
    Zhao JM; Wang HW; Xu ZF; Zhu L; Bai B; Ge XY
    Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):299-302. PubMed ID: 15949295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2.
    Snaddon J; Smith ML; Neat M; Cambal-Parrales M; Dixon-McIver A; Arch R; Amess JA; Rohatiner AZ; Lister TA; Fitzgibbon J
    Genes Chromosomes Cancer; 2003 May; 37(1):72-8. PubMed ID: 12661007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation of C/EBPalpha predisposes to the development of myeloid leukemia in a retroviral insertional mutagenesis screen.
    Hasemann MS; Damgaard I; Schuster MB; Theilgaard-Mönch K; Sørensen AB; Mrsic A; Krugers T; Ylstra B; Pedersen FS; Nerlov C; Porse BT
    Blood; 2008 Apr; 111(8):4309-21. PubMed ID: 18212247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia.
    Zhu YM; Foroni L; McQuaker IG; Papaioannou M; Haynes A; Russell HH
    Br J Cancer; 1999 Mar; 79(7-8):1151-7. PubMed ID: 10098750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C/EBPalpha mutations in acute myeloid leukaemias.
    Nerlov C
    Nat Rev Cancer; 2004 May; 4(5):394-400. PubMed ID: 15122210
    [No Abstract]   [Full Text] [Related]  

  • 18. C/EBPα in normal and malignant myelopoiesis.
    Friedman AD
    Int J Hematol; 2015 Apr; 101(4):330-41. PubMed ID: 25753223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
    Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC
    Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
    Pabst T; Mueller BU; Zhang P; Radomska HS; Narravula S; Schnittger S; Behre G; Hiddemann W; Tenen DG
    Nat Genet; 2001 Mar; 27(3):263-70. PubMed ID: 11242107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.